Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
News
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/c3/3e/fc/c33efcc2-426a-8ca0-5d5b-0d10f7b86c3d/mza_13682132506709836028.jpg/600x600bb.jpg
The TBPod
Actnet
44 episodes
5 months ago
Associate Professor Nicolas Alan Menzies, from the School of Global Health and Population at the Harvard T.H. Chan School of Public Health in Boston, Massachusetts, joins Dr Andrew Burke to discuss his research on the contribution of post-TB sequelae to life-years and quality-adjusted life-years lost due to TB disease in the United States. Drawing on data from both U.S. and Brazilian cohorts, he explores how a significant portion of TB’s health burden, including elevated mortality and reduced...
Show more...
Education
News,
Health & Fitness,
Medicine
RSS
All content for The TBPod is the property of Actnet and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Associate Professor Nicolas Alan Menzies, from the School of Global Health and Population at the Harvard T.H. Chan School of Public Health in Boston, Massachusetts, joins Dr Andrew Burke to discuss his research on the contribution of post-TB sequelae to life-years and quality-adjusted life-years lost due to TB disease in the United States. Drawing on data from both U.S. and Brazilian cohorts, he explores how a significant portion of TB’s health burden, including elevated mortality and reduced...
Show more...
Education
News,
Health & Fitness,
Medicine
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/c3/3e/fc/c33efcc2-426a-8ca0-5d5b-0d10f7b86c3d/mza_13682132506709836028.jpg/600x600bb.jpg
MTBVAC - one of the most promising new TB Vaccines with Dr Carlos Martín Montañés
The TBPod
42 minutes
1 year ago
MTBVAC - one of the most promising new TB Vaccines with Dr Carlos Martín Montañés
Today we discuss the MTBVAC with Dr Montañés. MTBVAC is an attenuated vaccine from a human mycobacterial isolate which has just progressed to a phase 3 trial and shown very promising results in the phase 2 study. Dr Montañés has been involved in this project for over a decade and has an incredible insight into the development and promise of this vaccine for global TB epidemiology.ReferencesMartín, Carlos, et al. "MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG...
The TBPod
Associate Professor Nicolas Alan Menzies, from the School of Global Health and Population at the Harvard T.H. Chan School of Public Health in Boston, Massachusetts, joins Dr Andrew Burke to discuss his research on the contribution of post-TB sequelae to life-years and quality-adjusted life-years lost due to TB disease in the United States. Drawing on data from both U.S. and Brazilian cohorts, he explores how a significant portion of TB’s health burden, including elevated mortality and reduced...